New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
ctDNA shapes anti-EGFR rechallenge strategies in metastatic colorectal cancer
Recent research shows that molecular monitoring is key to identify a patient-tailored window of opportunity for rechallenge
What is next for radiopharmaceuticals in NETs?
While early-phase findings confirm the efficacy and mild toxicity of radiopharmaceuticals, patient selection and logistical issues limit their integration into broad clinical practice
A novel off-the-shelf cancer vaccine shows some potential in PD-L1-negative patients with advanced melanoma
Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field
Zanzalintinib plus atezolizumab shows activity in metastatic colorectal cancer with microsatellite stable disease
Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases
Promising novel strategies to boost anticancer immunity in NECs
Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment
Novel immunotherapy combinations address unmet needs in liver cancers
Potentially practice-changing data were presented for atezolizumab plus bevacizumab, and camrelizumab plus rivoceranib in hepatocellular carcinoma
Research in pancreatic adenocarcinoma targets antibody-drug conjugates and oncolytic viruses
While telisotuzumab adizutecan demonstrated early antitumour activity, only modest benefits were seen with VCN-01 added to standard care
Sustained benefits of neoadjuvant immunotherapy demonstrated in resectable melanoma
Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies
Disitamab vedotin plus immunotherapy almost doubles overall survival in advanced HER2 expressing urothelial cancer
The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed